in Cancer Research

Mikhail Blagosklonny on Aging and Disease Prevention

Mikhail Blagosklonny, is a scientist who studies cancer and aging. He attended the First Pavlov State Medical University of St. Peterburg to earn both his M.D. in internal medicine and Ph.D of experimental medicine and cardiology. He was a professor of oncology at Rosswell Park Institute in New York.In 2002, he was appointed the position of associate professor of medicine for the New York Medical College in Valhalla, New York. Shortly afterwards he went on to become the senior scientist at Ordway Research Institute in Albany, New York. Where he remained in this position until 2009, when Rosswell Park Cancer Institute appointed him professor of oncology.Until Mikhail Blagosklonny and his studies proved different, one could count on the fact that their body was going to age. Age in the manner of there being the occurrence of a functional decline and random molecular damage, this process is something we humans have come to accept as the normal aging process. This process of aging could not be prevented, at least until now.

The discovery of Everolimus, a rapamycin analog, was found to be the turning point in the human quest for immortality, when it was found that this drug could actually boost the immunity of old humans. This was cause for many to celebrate as the year 2014 came to a close.The hyperfunction theory gives aging the description of being a growth continuum, created by a pathway of signals called TOR (target of Rapamycin). This TOR-centric model believes Rapamycin, and other rapalogs like it, can be an aid in the treatment of age and disease prevention in humans. When taken in a prescribed dosage , rapamycin and similar analogs, not only can but most certainly will extend the life-span a a healthy adult. However this theory has been ridiculed by opponents and anonymous peer-reviewers, it was predicted in 2008 that all the nay-sayers of the theory would, in five years, “be taking the TOR-centric model for granted”, in which this prediction has been proven correct.

It was actually in 2006 when rapamycin was first approved for its clinical use and was made readily available for immediate use. Rapamycin can be used in the treatment of cancer, cardiovascular and autoimmune diseases, also metabolic disorders, and other diseases of aging from osteoporosis to Alzheimer’s. It has been found for rapamycin to be the most effective if it’s used as an anti-aging drug, to slow down senescence and for disease prevention. Rapamycin is safe enough to be administered to transplant patients on a daily dosage. It has been found that rapamycin “eliminates hyper-immunity rather than suppressing immunity.”Rapamycin is safe enough for daily, oral consumption, it is non-toxic and well suitable. Studies done both preclinical and clinical have proven that it has promising use for age-related diseases, it has “anti-tumor, bone-sparing, calorie restriction-mimicking side effects.” After further review has been done on rapamycin, it has been proven that it has life-extending agents to produce immunostimultory activities when administered in the proper dosages. It is truly a wonder drug in the treatment of aging and disease prevention.

Write a Comment

Comment